Anti-CD9 monoclonal antibody-stimulated invasion of endometrial cancer cell lines in vitro: possible inhibitory effect of CD9 in endometrial cancer invasion.
Cell surface marker CD9 has been reported to play a role in inhibiting trophoblastic cell invasion. Since the invasive properties of cancer cells may resemble those of trophoblasts, we decided to investigate the role of CD9 in the invasion of endometrial cancer cells. In normal human endometrium, CD9 was found to be constitutively expressed on epithelial cells, as reported previously. While epithelial cells of endometrial hyperplasia (n = 5) were also positive for the expression of CD9, endometrial adenocarcinomas (n = 15) showed reduced expression. In order to clarify the significance of this reduced CD9 expression in endometrial cancer, an in-vitro invasion assay system was used to assess the effect of anti-CD9 monoclonal antibody (mAb) on the invasive properties of endometrial cancer cell line. Anti-CD9 mAb significantly enhanced invasion of the RL95-2 and Ishikawa cell lines, without affecting cell proliferation. Since CD9 is associated with the integrin subunits beta(1), alpha(3) and alpha(6) in human endometrium, we investigated the functional relationship between CD9 and these integrins in the RL95-2 cell line. Monoclonal antibodies against the integrins beta(1), alpha(3) and alpha(6) inhibited RL95-2 cell invasion. However, anti-CD9 mAb continued to show a stimulatory effect on RL95-2 cell invasion after treatment with anti-integrin alpha(3) mAb. In contrast, the anti-CD9 mAb had no effect after treatment with the mAb for integrins alpha(6) and beta(1). These findings indicate that CD9 is involved in regulating the invasive properties of endometrial carcinoma cells and that this effect is partially mediated by integrin subunits alpha(6) and beta(1). Thus, CD9 appears to be involved in the prevention of endometrial cancer invasion.
Park
K R
KR
Department of Gynaecology and Obstetrics, Faculty of Medicine, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan.
Inoue
T
T
Ueda
M
M
Hirano
T
T
Higuchi
T
T
Konishi
I
I
Fujiwara
H
H
Fujii
S
S
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D004714:Endometrial Hyperplasia / Q000276:immunology / Q000473:pathology; D016889:Endometrial Neoplasms / Q000276:immunology* / Q000473:pathology*; D004717:Endometrium / Q000276:immunology; D004847:Epithelial Cells / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D039422:Integrin alpha3; D039503:Integrin alpha6; D019012:Integrin beta1 / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D016023:Integrins / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D008562:Membrane Glycoproteins; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012016:Reference Values; D060245:Tetraspanin 29; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C554869:CD9 protein, human; D039422:Integrin alpha3; D039503:Integrin alpha6; D019012:Integrin beta1; D016023:Integrins; D008562:Membrane Glycoproteins; D060245:Tetraspanin 29